The Safety of IDegLira Versus IdegAsp in T2DM Patients with Poor Glycemic Control

HAN Yirui; YU Hua; MA Jian; CUI Xiuling

doi:10.3969/j.issn.2096-305X.2025.06.013

Abstract：Objective To observe the clinical efficacy and safety of IDegLira and IdegAsp in patients with type 2 diabetes mellitus(T2DM)who have poor glycemic control.Methods A total of 100 patients with type 2 diabetes who visited the outpatient department or were hospitalized in the Endocrinology Department of the Third Affiliated Hospital of Jinzhou Medical University from December 2022 to December 2024 and had poor blood sugar control despite using one or more oral hypoglycemic drugs were selected.They were randomly divided into the experimental group and the control group,with 50 cases in each group.The experimental group was given IDegLira injection by subcutaneous injection,once a day.The initial dose was 10 U per day.The dosage of IDegLira was adjusted daily according to the changes in the patient's fasting blood glucose level.Each adjustment was 2 to 4 U.The control group was given IdegAsp,with an initial dose of 0.4～0.5 U/kg/d.The insulin dose was evenly distributed 1∶1 before breakfast and dinner.The dose of IdegAsp for the next morning's breakfast was adjusted based on the blood glucose level before dinner the previous day,and the dose for the next evening's dinner was adjusted based on the blood glucose level before breakfast on that day.Each adjustment was 2-4 U.The observation period was 12 weeks.Waist circumference,body weight,body mass index(BMI),blood pressure,fasting blood glucose,2-hour blood glucose,glycosylated hemoglobin,fasting serum C-peptide,serum 2-hour C-peptide,triglycerides,total cholesterol,high-density lipoprotein cholesterol,low-density lipoprotein cholesterol,visceral fat content,the proportion of patients with blood glucose control,and adverse reactions were measured before treatment and at the 12th week after treatment.Results(1)After treatment,the waist circumference,BMI,and visceral fat of the experimental group were significantly lower than those of the control group,with a statistically significant difference(P＜0.05).(2)After treatment,fasting blood glucose(FBG),2 h PG,and HbA1c in both groups decreased significantly compared with those before treatment,and the differences were statistically significant(P＜0.01);however,there was no statistically significant difference between the two groups(P＞0.05).There was no statistically significant difference in the proportion of patients who achieved the blood glucose target(P＞0.05).(3)After treatment,the body weight,BMI,systolic blood pressure,triglycerides,total cholesterol,low-density lipoprotein cholesterol,and visceral fat content of the experimental group were lower than those before treatment,with statistically significant differences(P＜0.05),while its high-density lipoprotein cholesterol was higher than that before treatment,with a statistically significant difference(P＜0.05).In the control group,the high-density lipoprotein cholesterol after treatment was higher than that before treatment,and the difference was statistically significant(P＜0.05).(4)In the control group,3 cases of mild hypoglycemia occurred;in the experimental group,2 cases of gastrointestinal reactions occurred.There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Both IDegLira and IdegAsp can significantly reduce blood glucose levels in T2DM patients with poor glycemic control.IDegLira can reduce waist circumference,decrease body weight,lower blood pressure,improve blood lipids,and reduce visceral fat content.Additionally,it has a lower incidence of hypoglycemia and high safety,making it worthy of clinical promotion and application.